Travere reports Q3 2026 results, FILSPARI sales climb as pipeline advances

Travere Therapeutics reported third quarter 2026 financial results on November 2, 2026. U.S. net product sales of FILSPARI totaled $200.2 million in the third quarter of 2026, representing 120% growth year-over-year.¹ Patient demand across IgAN and FSGS resulted in 1932 new patient start forms received during the third quarter of 2026.¹

On the pipeline, the company is continuing to enroll new patients in the pivotal Phase 3 HARMONY Study, with topline data anticipated in 2H 2027.¹ The HARMONY Study is expected to enroll approximately 70 patients aged 12 to 65 with plasma total homocysteine levels of 50 µM or higher, with the primary endpoint being change from baseline in plasma tHcy levels averaged across weeks 6 through 12 compared with placebo, and durability of response through Week 24 as a key secondary endpoint.¹

For civorebrutinib, development planning is underway, with the company anticipating submission of a U.S. IND by year-end to enable dosing studies, followed by regulatory engagement to support late-stage clinical studies.¹ In the third quarter, the company recognized a $113.1 million IPR&D expense tied to the closing of its exclusive licensing and collaboration agreement with Everest Medicines for civorebrutinib.¹

In FSGS, study start-up is underway for the SPARLIGHT Study, a Phase 4, open-label, single-arm, multi-center study in a high-risk FSGS population of adult and pediatric participants, with the first patient expected by year-end.¹ Separately, the SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS has completed enrollment, with data anticipated in 2027.¹

On corporate matters, the company previously announced that Bradley L. Campbell will succeed Eric Dube as president and chief executive officer and join the Board of Directors effective December 1, 2026.¹

As of September 30, 2026, the company had cash, cash equivalents, and marketable securities of $471.8 million.¹